JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Waters Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

281.85 0.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

278.1

Max

282.52

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-110M

121M

Pardavimai

-211M

662M

P/E

Sektoriaus vid.

25.892

34.393

Pelnas, tenkantis vienai akcijai

2.95

Pelno marža

18.344

Darbuotojai

7,600

EBITDA

-193M

152M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+26.99% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-5.3B

17B

Ankstesnė atidarymo kaina

281.7

Ankstesnė uždarymo kaina

281.85

Naujienos nuotaikos

By Acuity

29%

71%

70 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Waters Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-14 14:26; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

2025-07-14 11:08; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

2025-07-15 18:32; UTC

Įsigijimai, susijungimai, perėmimai

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

2025-07-15 18:31; UTC

Įsigijimai, susijungimai, perėmimai

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

2025-07-14 16:53; UTC

Karštos akcijos

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

2025-07-14 16:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

2025-07-14 15:06; UTC

Įsigijimai, susijungimai, perėmimai

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

2025-07-14 14:11; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

2025-07-14 10:53; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

2025-07-14 10:21; UTC

Įsigijimai, susijungimai, perėmimai

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

2025-07-14 10:20; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

2025-07-14 10:19; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

2025-07-14 10:19; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

2025-07-14 10:18; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

2025-07-14 10:18; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

2025-07-14 10:17; UTC

Įsigijimai, susijungimai, perėmimai

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

2025-07-14 10:16; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

2025-07-14 10:16; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

2025-07-14 10:15; UTC

Įsigijimai, susijungimai, perėmimai

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

2025-07-14 10:15; UTC

Įsigijimai, susijungimai, perėmimai

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

Akcijų palyginimas

Kainos pokytis

Waters Corp Prognozė

Kainos tikslas

By TipRanks

26.99% į viršų

12 mėnesių prognozė

Vidutinis 354.67 USD  26.99%

Aukščiausias 465 USD

Žemiausias 300 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Waters Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

15 ratings

6

Pirkti

9

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

345.22 / 351.01Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

70 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Waters Corp

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.